Compounds > losartan

losartan and niacinamide

losartan has been researched along with niacinamide in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Aihara, Y; Douhara, A; Fukui, H; Kawaratani, H; Kitade, M; Moriya, K; Namisaki, T; Nishimura, N; Noguchi, R; Yoshiji, H1
Carter, JJ; Fretwell, LV; Woolard, J1
Abdelghany, RH; El-Ahwany, E; Goda, R; Helal, NS; Mahmoud, AAA; Saber, S1

Other Studies

4 other study(ies) available for losartan and niacinamide

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.
    Journal of gastroenterology, 2014, Volume: 49, Issue:10

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Hep G2 Cells; Humans; Liver Neoplasms, Experimental; Losartan; Male; Neovascularization, Pathologic; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Precancerous Conditions; Rats, Inbred F344; Sorafenib

2014
Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2017, Volume: 31, Issue:3

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Consciousness; Hemodynamics; Indazoles; Losartan; Male; Niacinamide; Phenylurea Compounds; Piperidines; Propranolol; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Regional Blood Flow; Sorafenib; Sulfonamides

2017
Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B.
    Toxicology letters, 2018, Oct-01, Volume: 295

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cyclin D1; Diethylnitrosamine; Fosinopril; Liver Neoplasms, Experimental; Losartan; Male; Matrix Metalloproteinase 2; Mice; NF-kappa B; NF-KappaB Inhibitor alpha; Niacinamide; Perindopril; Phenylurea Compounds; Phosphorylation; Renin-Angiotensin System; Signal Transduction; Sorafenib; Time Factors; Transcription Factor RelA; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A

2018